• Dec17

    Cancer Genetics Terminates Proposed Merger with NovellusDx

    RUTHERFORD, N.J., Dec. 17, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced that it has terminated the previously-announced merger agreement with NovellusDx, effective immediately. As a result of the termination of the merger agreement, the Company will […]

    » Continue Reading

  • Nov14

    Cancer Genetics Appoints Glenn Miles as Chief Financial Officer

    RUTHERFORD, N.J., Nov. 14, 2018 (GLOBE NEWSWIRE) — Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the appointment of Glenn Miles as Chief Financial Officer, effective November 26, 2018. Additionally, Mr. Igor Gitelman, Chief Accounting Officer of the Company will be departing […]

    » Continue Reading

  • Oct18

    Cancer Genetics Enters Strategic Partnership with Genecast Biotechnology to Commercialize Tissue of Origin® Test in China

    RUTHERFORD, N.J., Oct. 18, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced that it has signed an exclusive distribution agreement with Genecast Biotechnology to market, distribute and sell the Tissue of Origin® (TOO) Test in China. John A. […]

    » Continue Reading

  • Oct16

    Cancer Genetics Issues Letter to Shareholders

    RUTHERFORD, N.J., Oct. 16, 2018 (GLOBE NEWSWIRE) — Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the publication of a letter to shareholders from its Chief Executive Officer Jay Roberts. Dear Shareholders, As we approach the last few months of 2018, it […]

    » Continue Reading

  • Oct8

    Cancer Genetics and Cellaria Partner on Precision Medicine Tools

    Collaboration focused on developing pharmacology models to support biopharma R&D RUTHERFORD, N.J., Oct. 08, 2018 (GLOBE NEWSWIRE) — Cancer Genetics (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, and Cellaria, LLC, a scientific innovator that develops revolutionary new cancer models, today announced a new collaboration to […]

    » Continue Reading

  • Sep26

    Cancer Genetics Enters Supply Agreement with Agilent Technologies

    Probes for CGI’s FISH-based HPV-Associated Cancer Test (FHACT®) test to be manufactured by Agilent RUTHERFORD, N.J., Sept. 25, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced that it has signed a non-exclusive supply agreement with Agilent Technologies […]

    » Continue Reading

  • Sep20

    Cancer Genetics Offers Oncomine Comprehensive Assay to Drive Clinical Trials

    RUTHERFORD, N.J., Sept. 20, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomics through molecular markers and diagnostics, today announced the successful CLIA validation and commercial launch of Thermo Fisher Scientific’s next-generation sequencing (NGS) Oncomine™ Comprehensive Assay v3 for biopharma clinical trials. John A. Roberts, […]

    » Continue Reading

  • Sep18

    Cancer Genetics and NovellusDx Sign Definitive Agreement to Merge

    Transaction to Create a Leader in Precision Oncology RUTHERFORD, N.J. and JERUSALEM, Sept. 18, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, and NovellusDx, Ltd., a leader in functional genomics, today announced the signing of a definitive agreement […]

    » Continue Reading

  • Aug14

    Cancer Genetics Reports Second Quarter 2018 Financial Results and Provides Strategic Business Updates

    Conference call at 8:30 a.m. ET, Tuesday, August 14, 2018 RUTHERFORD, N.J., Aug. 14, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular markers and diagnostics, today announced financial and operating results for the second quarter ended June 30, 2018 as well […]

    » Continue Reading

  • Aug7

    Cancer Genetics to Report Second Quarter 2018 Financial Results on August 14, 2018

    Conference call at 8:30 a.m. EDT, Tuesday, August 14, 2018 RUTHERFORD, N.J., Aug. 07, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that it will release its financial results for the second quarter ended June 30, 2018 on Tuesday, August […]

    » Continue Reading

  • Jul18

    Cancer Genetics Closes $2.625 million Convertible Note Financing

    RUTHERFORD, N.J., July 18, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the closing of a $2.625 million convertible note financing with a single institutional investor. John A. Roberts, Chief Executive Officer of Cancer Genetics, commented, “This capital raise helps […]

    » Continue Reading

  • Jun12

    Cancer Genetics Strengthens Management Team with Appointment of Michael McCartney as Chief Commercial Officer

    Executive appointment underscores continued execution of new corporate strategy of expanding Biopharma and Discovery businesses RUTHERFORD, N.J., June 12, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the appointment Michael McCartney as the Company’s Chief Commercial Officer, effective immediately. Mr. […]

    » Continue Reading

  • May15

    Cancer Genetics Reports First Quarter 2018 Financial Results and Provides Strategic Business Updates

    Conference call at 8:30 a.m. EDT, Tuesday, May 15, 2018 RUTHERFORD, N.J., May 15, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced financial and operating results for the first quarter ended March 31, 2018 as well as an update on […]

    » Continue Reading

  • May10

    Cancer Genetics to Report First Quarter 2018 Financial Results on May 15, 2018

    Conference call at 8:30 a.m. EDT, Tuesday, May 15, 2018 RUTHERFORD, N.J., May 10, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that it will release its financial results for the first quarter ended March 31, 2018 on Tuesday, May 15, […]

    » Continue Reading

  • Apr27

    Cancer Genetics Announces Sale of India Operations to REPROCELL Incorporated

    Execution of 2018 Transformation Plan is on Target RUTHERFORD, N.J., April 27, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that it has completed the sale of BioServe Biotechnologies (India) Private Limited, a wholly-owned subsidiary of Cancer Genetics to biomedical […]

    » Continue Reading

  • Apr16

    Cancer Genetics’ Unique Tissue of Origin Test (TOO®) Receives Special FDA 510(k) Clearance

    RUTHERFORD, N.J., April 16, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that it has received special 510(k) clearance from the U. S. Food and Drug Administration (FDA) for its Tissue of Origin test (TOO®) following modifications made to test […]

    » Continue Reading

  • Apr2

    Cancer Genetics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Strategic Business Updates

    Conference call at 4:30 p.m. EDT, Monday, April 2, 2018 RUTHERFORD, N.J., April 02, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced financial and operating results for the fourth quarter and full year ended December 31, 2017 as well as an […]

    » Continue Reading

  • Mar26

    Cancer Genetics to Host Fourth Quarter and Full Year 2017 Financial Results

    Conference call at 4:30 p.m. EDT, Monday, April 2, 2018 RUTHERFORD, N.J., March 26, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2017 on […]

    » Continue Reading

  • Feb5

    Cancer Genetics, Inc. Chief Executive Officer Steps Down

    Board Appoints COO, Jay Roberts, Interim Chief Executive Officer RUTHERFORD, N.J., Feb. 05, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX) an emerging leader in enabling precision medicine for oncology through the use of molecular markers and information, announced today that Panna Sharma will be stepping down as President, Chief Executive Officer and a director […]

    » Continue Reading

  • Jan17

    Cancer Genetics Expands Its Industry-Leading Immuno-Oncology Panel, Complete::IO™, to be the Most Comprehensive for Immune Profiling & Monitoring

    – Simultaneously Assesses 27 Unique Immune Markers – Determines Optimal IO Therapies and Tracks Response and Resistance Mechanisms RUTHERFORD, N.J., Jan. 17, 2018 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. (Nasdaq:CGIX), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, today announced the expansion of its immuno-oncology (IO) panel, Complete::IO™, to include […]

    » Continue Reading